Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAR: TRI-BI vs Immediate BI in ARV-naive HIV-1 Patients
NCT04051970Phase 3Terminated
- Sponsor
- ANRS
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir, tenofovir alafenamide, emtricitabine, lamivudine, dolutegravir in human immunodeficiency virus infection (HIV), sponsored by ANRS. Started Nov 2019; status: terminated.
02
Drugs
tenofovirtenofovir alafenamideemtricitabinelamivudinedolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04051970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051970.